Surrozen, Inc. (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Buys 1,034,482 Shares

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III acquired 1,034,482 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average price of $11.60 per share, with a total value of $11,999,991.20. Following the completion of the transaction, the insider now owns 795,411 shares of the company’s stock, valued at $9,226,767.60. This trade represents a -432.71 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Surrozen Price Performance

Shares of NASDAQ SRZN traded down $0.38 during trading on Friday, hitting $11.01. 5,246 shares of the company traded hands, compared to its average volume of 22,355. The business’s fifty day moving average is $11.37 and its 200 day moving average is $10.94. Surrozen, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $18.17.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in Surrozen by 26.1% in the fourth quarter. Geode Capital Management LLC now owns 22,391 shares of the company’s stock valued at $321,000 after acquiring an additional 4,630 shares during the period. Trustees of Columbia University in the City of New York bought a new position in shares of Surrozen in the 4th quarter worth $688,000. Adage Capital Partners GP L.L.C. acquired a new stake in Surrozen in the 4th quarter valued at $928,000. Regents of The University of California bought a new stake in Surrozen during the 4th quarter valued at $1,912,000. Finally, Stonepine Capital Management LLC increased its stake in Surrozen by 24.7% during the 4th quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock valued at $1,969,000 after purchasing an additional 27,200 shares in the last quarter. Institutional investors own 66.57% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on SRZN shares. Guggenheim raised shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price target on the stock in a research report on Friday, January 3rd. HC Wainwright assumed coverage on Surrozen in a research report on Thursday, January 30th. They set a “buy” rating and a $32.00 target price on the stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.